Natera, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
NTRA Nasdaq 3840 www.natera.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Natera, Inc.

Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA - Jan 12th, 2026 8:00 am
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth - Jan 11th, 2026 8:48 pm
Breakeven On The Horizon For Natera, Inc. (NASDAQ:NTRA) - Jan 11th, 2026 7:00 am
2 Cash-Heavy Stocks to Keep an Eye On and 1 We Question - Jan 10th, 2026 9:31 pm
How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story - Jan 9th, 2026 1:15 am
Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans - Jan 8th, 2026 10:08 pm
Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial - Jan 8th, 2026 2:01 pm
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study - Jan 8th, 2026 6:50 am
Dr. Paul Billings Joins Lindus Health's Scientific Advisory Board - Jan 8th, 2026 6:00 am
Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls - Jan 7th, 2026 7:41 am
Insiders At Natera Sold US$47m In Stock, Alluding To Potential Weakness - Jan 7th, 2026 7:00 am
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonald’s, Moderna, and More - Jan 7th, 2026 6:04 am
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer - Jan 7th, 2026 6:00 am
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch - Jan 6th, 2026 6:00 am
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI - Jan 5th, 2026 5:25 pm
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology - Jan 5th, 2026 5:00 am
Exploring 3 High Growth Tech Stocks In The US Market - Jan 2nd, 2026 10:38 am
Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study - Dec 31st, 2025 9:56 am
Medical Stock Hovers Near Buy Point After 46% Gain - Dec 30th, 2025 12:16 pm
3 Growth Stocks with Explosive Upside - Dec 28th, 2025 9:33 pm